Birmingham raid: over 12,000 fake weight-loss pens seized

Written and edited by Yianni Kiromitis. Published 16 October 2026. Updated 24 October 2026. Original sources checked 16 October 2026; sources for this news update rechecked 24 October 2026. The preceding version records scientific review by Eleni Kiromitis, BSc (Hons) Biomedical Science, completed 16 October 2026. That scientific review applies to the preceding version. The publisher has confirmed clinical approval of this update by Dr Stavroula Nikitopoulou (Dr Stavy), GMC 6092503. Independent clinical review is pending.

MHRA officers and West Midlands Police seized over 12,000 fake weight-loss pens from an industrial unit in Birmingham on 14 October 2026. The regulator valued the medicines at about £2 million. Officers also found packaging for around 30,000 further products, not another 30,000 filled pens. [1]

The MHRA announced the seizure on 15 October. Its release describes fake retatrutide and tirzepatide pens, but does not publish laboratory results showing what the October products contained. The names on those products should not be treated as proof of their ingredients. [1]

The MHRA warning published on 26 October 2023 is also a separate incident. That notice described reactions suggesting possible insulin in potentially fake pens. It does not establish the contents of the October 2026 seizure. The dated counterfeit-product record keeps those findings and their limits separate.

This is a new entry in the documented record of counterfeit and unauthorised weight-loss products. It must be kept separate from the February 2026 alert about falsified Mounjaro pens supplied through a Birmingham pharmacy.

What did officers find in Birmingham?

The confirmed seizure was over 12,000 pens and packaging for around 30,000 more products. The MHRA described the location as an industrial unit in Birmingham. Its enforcement spokesman said the products had not been assessed for safety, quality or effectiveness. [1]

The release does not identify a seller, provide a consumer batch list or establish a link to The Private Pharmacy Clinic. It also does not state that every seized pen contained the same substance or was contaminated. Those details remain unreported in this source. [1]

Is this the same incident as the fake Mounjaro pharmacy alert?

No connection is established in the sources checked. The October warehouse raid and the February pharmacy alert are distinct reports. The fact that both concern Birmingham does not establish a shared supplier or operation. [1] [2]

On 24 February 2026, the MHRA warned that five falsified Mounjaro KwikPen 15 mg pens had been identified after supply through The Private Pharmacy Clinic in Birmingham. Chemist+Druggist reported that alert on 25 February. These are the dates of the earlier reports, not new findings from October. [2] [3]

The February pens carried batch number D873576. That number belongs to a genuine 7.5 mg Mounjaro batch. The MHRA said genuine pens at that strength were not affected. The warning applies to the combination of 15 mg and D873576; the batch number alone is not the whole check. [2]

The regulator said faults helped reveal the February fakes: the dose knob came off during use in all but one case. A working mechanism, however, is not a test of what a pen contains or how it was made. [2]

Can a fake pen contain the real active ingredient?

Yes. The MHRA’s February notice says recovered falsified pens were tested and contained tirzepatide. It also says their manufacturing conditions were unknown and sterility could not be assured. Finding the expected ingredient did not make those pens genuine or safe. [2]

This is a useful distinction when reading the October news. An identity test answers which substance was detected. It does not, by itself, establish the amount, sterility, storage history or quality of the whole product. Nor can a result from February be transferred to pens seized in October.

The tirzepatide evidence profile explains why evidence for an authorised medicine does not verify a different product sold under the same molecule name.

What did the MHRA say about retatrutide?

In its 15 October statement, the MHRA said retatrutide had not been authorised for use in the UK. It said products sold as retatrutide outside legitimate clinical trials were being supplied illegally and could pose serious health risks. [1]

That statement concerns products being supplied as medicines. It should not be expanded into a claim about every possible research transaction. For readers, the key point is that an online pen does not become an authorised treatment because its label names a compound being studied in trials. Read the retatrutide trial and UK-status profile for the wider context.

What should someone do about a suspect pen?

Use the advice that matches the problem. The specific February batch alert and a general concern about an October-related product are not interchangeable.

• For a Mounjaro 15 mg pen marked D873576: the MHRA says not to use it. Keep it safely and email info@mhra.gov.uk with “Mounjaro Pens” in the subject line. The notice says the agency will arrange collection. Ask a healthcare professional if you are unsure whether your pen matches. [2]
• For a suspected side effect, defective pen or counterfeit medicine: use the official medicine-problem reporting route, including Yellow Card. A report does not replace medical care. [4]
• For a suspicious online seller: use the MHRA suspicious-seller reporting service. [5]

The MHRA advises people considering GLP-1 treatment to speak to a healthcare professional and obtain medicines through a registered pharmacy against a valid prescription. The earlier pharmacy incident remains a reason to act on product alerts and faults even when a product arrived through a pharmacy. [1] [2]

For the broader distinction, read grey-market versus prescribed GLP-1 products.